Pages that link to "Q77355742"
Jump to navigation
Jump to search
The following pages link to Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver (Q77355742):
Displaying 50 items.
- XMetDB: an open access database for xenobiotic metabolism (Q26899110) (← links)
- Inhibitory effect of medroxyprogesterone acetate on human liver cytochrome P450 enzymes (Q28237104) (← links)
- Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes (Q28345530) (← links)
- Inhibitory Effects of Green Tea and (-)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein (Q28548692) (← links)
- Membrane transporters in drug development (Q29616802) (← links)
- Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver (Q30595605) (← links)
- Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? (Q30778435) (← links)
- Database analyses for the prediction of in vivo drug-drug interactions from in vitro data (Q30913359) (← links)
- Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant (Q31012256) (← links)
- Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation (Q31034463) (← links)
- Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. (Q31061538) (← links)
- A Bayesian meta-analysis on published sample mean and variance pharmacokinetic data with application to drug-drug interaction prediction (Q33383326) (← links)
- Modulation of pharmacokinetics of theophylline by antofloxacin, a novel 8-amino-fluoroquinolone, in humans (Q33566153) (← links)
- Interplay of drug metabolism and transport: a real phenomenon or an artifact of the site of measurement? (Q33570999) (← links)
- Pharmacokinetic considerations in the eradication of Helicobacter pylori (Q33882633) (← links)
- Sulindac and its metabolites inhibit multiple transport proteins in rat and human hepatocytes. (Q34035243) (← links)
- Impact of Ignoring Extraction Ratio When Predicting Drug-Drug Interactions, Fraction Metabolized, and Intestinal First-Pass Contribution (Q34257513) (← links)
- Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models. (Q34476096) (← links)
- Clinically significant interactions with drugs used in the treatment of tuberculosis (Q34558656) (← links)
- Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin (Q34571070) (← links)
- Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects (Q34585824) (← links)
- Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins (Q34714353) (← links)
- Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies. (Q35049310) (← links)
- Inhibition of secreted phospholipase A2 by neuron survival and anti-inflammatory peptide CHEC-9 (Q35110642) (← links)
- Estimation of the binding modes with important human cytochrome P450 enzymes, drug interaction potential, pharmacokinetics, and hepatotoxicity of ginger components using molecular docking, computational, and pharmacokinetic modeling studies (Q35113280) (← links)
- Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4. (Q35166632) (← links)
- Factors affecting the clinical development of cytochrome p450 3A substrates (Q35196196) (← links)
- Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms (Q35566353) (← links)
- In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia (Q35826342) (← links)
- Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics (Q35827223) (← links)
- Irreversible binding of an anticancer compound (BI-94) to plasma proteins (Q36005906) (← links)
- Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. (Q36068699) (← links)
- In vivo information-guided prediction approach for assessing the risks of drug-drug interactions associated with circulating inhibitory metabolites (Q36105348) (← links)
- A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors (Q36125455) (← links)
- Drug transporters in pharmacokinetics (Q36419290) (← links)
- CYP induction-mediated drug interactions: in vitro assessment and clinical implications (Q36485692) (← links)
- Inhibition of Efavirenz Metabolism by Sertraline and Nortriptyline and Their Effect on Efavirenz Plasma Concentrations (Q36571936) (← links)
- Inhibitory effects of phytochemicals on metabolic capabilities of CYP2D6(*)1 and CYP2D6(*)10 using cell-based models in vitro (Q36745814) (← links)
- Interaction of silymarin flavonolignans with organic anion-transporting polypeptides (Q36776621) (← links)
- Significant Pharmacokinetic Interactions Between Quinine and Ampicillin-Cloxacillin Combination (Q36924000) (← links)
- Drug-drug interaction studies: regulatory guidance and an industry perspective (Q36951933) (← links)
- Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. (Q37121662) (← links)
- Downregulation of Organic Anion Transporting Polypeptide (OATP) 1B1 Transport Function by Lysosomotropic Drug Chloroquine: Implication in OATP-Mediated Drug-Drug Interactions (Q37145705) (← links)
- In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions (Q37237438) (← links)
- A new probabilistic rule for drug-dug interaction prediction (Q37333015) (← links)
- Mechanism of autoinduction of methadone N-demethylation in human hepatocytes (Q37409042) (← links)
- Pharmacology of morphine in obese patients: clinical implications (Q37863760) (← links)
- Predicting the clinical relevance of drug interactions from pre-approval studies. (Q37610142) (← links)
- Clinical Importance of OATP1B1 and OATP1B3 in DrugDrug Interactions (Q37836255) (← links)
- Characterization of 22 Antituberculosis Drugs for Inhibitory Interaction Potential on Organic Anionic Transporter Polypeptide (OATP)-Mediated Uptake. (Q38895149) (← links)